Key result
Precision medicine approaches, including molecular and genetic techniques, are actively being pursued in Ewing sarcoma to refine prognosis, influence therapeutic selection, and monitor disease.
This review discusses the current and emerging roles of precision medicine in the diagnosis, treatment, and monitoring of Ewing sarcoma.
Supports pursuit of precision approaches in Ewing sarcoma; leaves open whether they improve outcomes or warrant clinical adoption.
Advancements in molecular and genetic techniques have significantly furthered our biological understanding of Ewing sarcoma (ES). ES is typified by a driving TET–ETS fusion with an otherwise relatively quiet genome. Detection of one of several characteristic fusions, most commonly EWSR1–FLI1 , is the gold standard for diagnosis. We discuss the current role of precision medicine in the diagnosis, treatment, and monitoring of ES. Continued efforts toward molecularly guided approaches are actively being pursued in ES to better refine prognosis, identify germline markers of disease susceptibility, influence therapeutic selection, effectively monitor disease activity in real time, and identify genetic and immunotherapeutic targets for therapeutic development.
No takes yet. Share an insight, caveat, or question.
Rizk et al. (2019) conducted a review in Ewing sarcoma. Precision medicine approaches was evaluated. Precision medicine approaches, including molecular and genetic techniques, are actively being pursued in Ewing sarcoma to refine prognosis, influence therapeutic selection, and monitor disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: